- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- OTX-TKI, Aflibercept
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 73 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
- Interventions
- observational study, VOY-101
- Other · Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
- Interventions
- brolucuzumab 6 mg IVT
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Abilene, Texas
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Biological
- Lead sponsor
- Xbrane Biopharma AB
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- RetnaGene AMD LDT
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- SOK583A1
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 5
- States / cities
- Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 53 more
- Conditions
- Macular Degeneration
- Interventions
- pazopanib eye drops
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Miami, Florida • Winter Haven, Florida + 6 more
- Conditions
- Macular Degeneration
- Interventions
- Microplasmin, Placebo control
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- CLS-AX, Aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
- Genetic
- Lead sponsor
- Olix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more
- Conditions
- Wet Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab
- Drug
- Lead sponsor
- Kapil Kapoor
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Virginia Beach, Virginia
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Glen Burnie, Maryland
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- No Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Interventions
- EYE201
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
- Conditions
- Macular Degeneration
- Interventions
- Abicipar pegol
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SB15 (Proposed aflibercept biosimilar), Eylea (Aflibercept)
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Chevy Chase, Maryland • Abilene, Texas
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 87
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- ABP 938, Aflibercept
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
- Interventions
- UBX1325
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Huntington Beach, California • Miami, Florida + 5 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, bevacizumab or aflibercept, E10030 sham injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 100
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more